CYP2C19 and major depressive disorder: Finally, Peters et al. [63] studied the STAR*D cohort to determine whether pharmacokinetic genes, including CYP2C19 *2, *3, and *17 polymorphisms, could affect the response or tolerability to citalopram in patients with nonpsychotic MDD.